Trial Profile
A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary) ; Zonisamide (Primary) ; Lamotrigine; Sodium valproate
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms SANAD-II
- 22 Feb 2019 Planned End Date changed from 1 Feb 2018 to 30 Nov 2019.
- 22 Feb 2019 Status changed from completed to active, no longer recruiting.
- 13 Jul 2016 Status changed from recruiting to completed.